

The Digital Examiner

www.prostaidcalgary.org

271 May 2022

"If you want to lift yourself up, lift up someone else."

Booker T. Washington

Connect with us:

Information

Phone: 403-455-1916 info@prostaid.org

> **Brad Sterling President**

president@prostaid.org

Support Groups

Frank Altin Warriors

faltin@telusplanet.net

Wives, Partners & Caregivers info@prostaid.org

Newly Diagnosed info@prostaid.org

Mailing Address

PROSTAID Calgary Society

PO Box 72126 **RPO Glenmore Landing** Calgary, Alberta T2V 5H9 Phone: 403-455-1916

To subscribe to The **Digital Examiner** info@prostaid.org

PROSTAID Calgary is self-funded.

Click here to help us to continue our good work by donating on-line

Next General Meeting: Tuesday, May 10th, 2022 @ 7:30 pm via ZOOM

"Complementary Therapies in Cancer Care: What are they and how can they help?" Please RSVP to program.director@prostaid.org



Dr. Linda Carlson holds the Enbridge Research Chair in Psychosocial Oncology, is a Professor in Psychosocial Oncology, Cumming School of Medicine at the University of Calgary, and Adjunct Professor in the Department of Psychology.

She is the Director of Research and works as a Clinical Psychologist at the Department of Psychosocial Resources at the Tom Baker Cancer Centre, where she has worked since 1997.

She also holds a CIHR SPOR-funded mentorship chair in innovative clinical trials, which funds the TRACTION program (Training in Research And Clinical Trials in Integrative Oncology), supporting a multidisciplinary group of UofC fellows studying Integrative Oncology.

Dr. Carlson's research in Psychosocial Oncology, Integrative Oncology and Mindfulness-Based Cancer Recovery has been published in many high-impact journals and book chapters and she published a patient manual. She is regularly invited to present her work at international conferences, most recently in Netherlands, Switzerland, China, Australia, New Zealand, Africa, Israel and all across Canada and the USA. She presented a TEDx talk called Mindfulness for Personal and Collective Evolution in 2016, you can find the video here: https://www.youtube.com/watch?

v=QgZd5GvZ5Qs

Side Bar:

*MAY meeting will still be via **ZOOM** only. Carma House is opening on May 2, but with limited



programs and access.

- Watch for an email or letter in the mail from PROSTAID Calgary Society regarding updating our membership list. By replying you will be automatically entered to WIN a door prize of a Dinner for Two at the Ranchman's Club. Winner to be drawn at the AGM. June 21st.
- As always, page 2 is dedicated to what's new in research and any other news of interest to you, our members.
- Page 3 you will find a link to a new service being offered virtually by a primary care network, open to all seniors in the province.
- If you missed it, Page 4 includes a link to the PCRI (Prostate Cancer Research Institute) Video Updates.

As always, if you have topic suggestions for future meetings, please let me know.

Stay healthy, Dorothy

Dorothy Rodehutskors Program Director

What's new in RESEARCH:

<u>Symptoms Related to Bone Metastasis in Men Receiving Lutetium-177 PSMA-617 for Prostate Cancer</u>

- * Alicia Morgans is joined by Brian Gonzalez to discuss work he presented at GU ASCO 2022 on patient-reported quality of life metrics among men receiving prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
- March 2022 (Video)

<u>Treatment-Related Regret Among Men With Localized</u> Prostate Cancer Journal Club

- * This work aimed to assess the association between treatment approach, functional outcomes, patient expectations, and treatment-related regret among patients with localized prostate cancer.
- * December 2021

<u>Imaging and Novel Therapeutics: Navigating Paradigm</u> <u>Shifts in Clinical Trials for Early-Stage Disease</u>

- * Dr. Alicia Morgans presents on the rapid evolution of the prostate cancer treatment landscape. Highlighting the example of a fictious SuperDrug being investigated in the adjuvant setting following prostatectomy for high-risk localized disease, she emphasized that there have been dramatic recent changes in imaging which change how we approach this patient and their care.
- * February 2022

The Dark Side of PSMA: Pitfalls, Limits, and ADT

- * In this educational initiative, focusing on the knowledge of PSMA PET and PSMA theranostics, Drs Matthias Eiber and Thomas Langbein jointly prepared and Dr Eiber presents on the Dark Side of PSMA: Pitfalls, Limits, and ADT for prostate cancer.
- November 2021 (Video)

What's new generally:

<u>Are We Making Progress in Addressing Disparities in Prostate Cancer?</u>

- * Dr. Peter Black reviewed the prior three abstracts, focused on addressing the increased incidence and mortality in African American men (AAM) with prostate cancer. He framed his discussion around points brought up by a previous presenter, that prostate cancer outcomes could be equivalent by race if all patients received a timely diagnosis, had adequate staging and risk stratification, and received equitable and correct treatment delivery.
- * June 2021

Genomic Disparities Across Gleason Scores

- * Dr. Mahal begins by reviewing the case initially presented in this session by Dr. Carthon. To recall, this was an 81-year-old man with a history of Gleason 4+3=7 prostate cancer who was initially diagnosed in 2005 as a result of urinary symptoms, without PSA screening.
- * June 2021

<u>Caring for the Whole Patient: The Role of Advocacy in Patient Care</u>

- Dr. Giles notes that today's reality of patient advocacy is as follows: Patient advocacy also operates at the local/national, European, and global level:
- Local/national: information and support, national policy, awareness, access (reimbursement)
- European: EU policy, frameworks, systems, research collaboration, access (systems, inequalities), evidence generation
- Global: some European-based organizations are Europe-resident global coalitions
- * April 2022
- ** Not specific to prostate cancer, but could apply to all cancers.

Articles of Interest:

Everyone:

For Newly Diagnosed:

Pre-Diagnostic Markers in Prostate Cancer

- * Joseph Wagner led a course entitled "Incorporating Genomic Testing For Prostate Cancer into Your Practice". Following an introduction to genomic testing by Dr. Wagner, Dr. Cooperberg discussed the role of pre-diagnostic markers.
- * May 2021

Real-World Health-Related Quality of Life and Caregiver Needs in Patients with mHSPC and mCRPC

- 2022 GU ASCO Annual meeting included a prostate cancer session highlighting work from Dr. Mark Boye and colleagues presenting results of their study assessing real-world health-related quality of life (HRQoL) and caregiver needs in patients with metastatic hormone-sensitive (mHSPC) and metastatic castration-resistant prostate cancer (mCRPC).
- February2022



Pluvicto™ (177Lu-PSMA-617) Indications for Clinical
Use in PSMA Positive Metastatic Castration-Resistant
Prostate Cancer mCRPC

- * Oliver Sartor joins Phillip Koo to discuss the United State FDA approval of Pluvicto™ (177Lu-PSMA -617) as the first targeted radioligand therapy for the treatment of PSMA positive metastatic castration-resistant prostate cancer (mCRPC). They discuss currently enrolling in clinical trials with Pluvicto in the pre-chemotherapy treated mCRPC patient population. They look further into the future discussing other potential radioligand treatments of other beta emitters and alpha emitters.
- March 2022 (Video)

<u>Trends in Incidence of Metastatic Prostate Cancer in the US</u>

- * This study suggests that the incidence of mPCA is increasing and might be temporally associated with changes in clinical policy and/or practice (eg, USPSTF guidelines), which may explain such rapid changes in cancer epidemiological trends.
- * March 2022

OPEN to any Senior in the Province of

Alberta.

Seniors' Centre Without Walls - Edmonton Southside Primary Care Network | Edmonton Southside Primary Care Network

All the benefits of a seniors' centre from the comfort of your own home! Seniors' Centre Without Walls is a free, phone-based program that offers a variety of interactive health and well-being information sessions, recreational activities, and friendly conversations.

www.edmontonsouthsidepcn.ca

Digital Examiner Page 4

EVENT/Research Studies:

Event link here: PCRI 2022 Replays

2022 PCRI MOYAD + SCHOLZ MID-YEAR UPDATE

WATCH THE REPLAYS





REPLAY! CLICK THE VIDEO ABOVE TO WATCH DAY 1

REPLAY! CLICK THE VIDEO ABOVE TO WATCH DAY 2

Videos:

Appropriate Use Criteria for PSMA PET Imaging

- * To guide referring and imaging physicians to use PSMA PET imaging agents appropriately, several organizations worked collaboratively to develop criteria for the appropriate use of this new imaging technology.
- * March 2022

